Featured Research

from universities, journals, and other organizations

pH-sensitive liposomal cisplatin improves peritoneal carcinomatosis treatment without side-effects

Date:
August 27, 2012
Source:
Society for Experimental Biology and Medicine
Summary:
Scientists have developed and characterized a circulating and pH-sensitive liposome containing cisplatin (SpHL-CDDP) aiming to promote the release of cisplatin near the tumor as well as decreasing toxicity. The development of analog drugs and new formulations are current strategies for increasing the effectiveness and safety of cisplatin as an anti-peritoneal carcinomatosis drug.

Scientists at the Oswaldo Cruz Foundation and Federal University of Minas Gerais, led by Dr. Andrιa Teixeira-Carvalho and Dr. Mτnica Cristina de Oliveira, have developed and characterized a circulating and pH-sensitive liposome containing cisplatin (SpHL-CDDP) aiming to promote the release of cisplatin near the tumor as well as decreasing toxicity. The development of analog drugs and new formulations are current strategies for increasing the effectiveness and safety of cisplatin as an anti-peritoneal carcinomatosis drug.

The results, which appear in the August 2012 issue of Experimental Biology and Medicine demonstrate that the treatment of initial or disseminated Ehrlich ascitic tumor-bearing Swiss mice with SpHL-CDDP improved the antitumor efficacy and decreased renal and bone marrow toxicity of cisplatin-based therapy.

"Peritoneal carcinomatosis is a serious concern in the treatment of abdominal tumors such as hepatic, gastric and gynecological tumors," says Dr. Oliveira. "The strategy of local chemotherapy is interesting due to the possibility to increase the therapeutic efficacy while minimizing systemic side-effects. SpHL-CDDP treatment was able to reduce cancer cell proliferation and increase survival, in the animal model, with no known toxicity clinical signs found in the free CDDP treatment." says Dr. Maroni.

These results open the possibility of future use of SpHL-CDDP in chemotherapy of peritoneal carcinomatosis. "New studies are underway in our research group to investigate the signaling pathways of cell death as well as use of high doses of SpHL-CDDP for the treatment of peritoneal carcinomatosis," says Dr. Teixeira-Carvalho.

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine, said: "This very interesting study has utilized a new pH-sensitive circulating liposome containing cisplatin formulation which decreased cancer proliferation and drug toxicity in a mouse model. This provides the basis for further translational testing of this formulation leading to clinical trials aimed at more effective treatment of abdominal tumors."


Story Source:

The above story is based on materials provided by Society for Experimental Biology and Medicine. Note: Materials may be edited for content and length.


Journal Reference:

  1. L. de Carvalho Maroni, A. C. de Oliveira Silveira, E. A. Leite, M. M. Melo, A. F. de Carvalho Ribeiro, G. D. Cassali, C. M. de Souza, E. M. Souza-Fagundes, I. R. Caldas, M. S. S. Araujo, O. A. Martins-Filho, M. C. de Oliveira, A. Teixeira-Carvalho. Antitumor effectiveness and toxicity of cisplatin-loaded long-circulating and pH-sensitive liposomes against Ehrlich ascitic tumor. Experimental Biology and Medicine, 2012; 237 (8): 973 DOI: 10.1258/ebm.2012.011432

Cite This Page:

Society for Experimental Biology and Medicine. "pH-sensitive liposomal cisplatin improves peritoneal carcinomatosis treatment without side-effects." ScienceDaily. ScienceDaily, 27 August 2012. <www.sciencedaily.com/releases/2012/08/120827113357.htm>.
Society for Experimental Biology and Medicine. (2012, August 27). pH-sensitive liposomal cisplatin improves peritoneal carcinomatosis treatment without side-effects. ScienceDaily. Retrieved September 1, 2014 from www.sciencedaily.com/releases/2012/08/120827113357.htm
Society for Experimental Biology and Medicine. "pH-sensitive liposomal cisplatin improves peritoneal carcinomatosis treatment without side-effects." ScienceDaily. www.sciencedaily.com/releases/2012/08/120827113357.htm (accessed September 1, 2014).

Share This




More Health & Medicine News

Monday, September 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) — A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) — Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com
California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

Reuters - US Online Video (Aug. 30, 2014) — California lawmakers pass a bill requiring universities to adopt "affirmative consent" language in their definitions of consensual sex, part of a nationwide drive to curb sexual assault on campuses. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
New Drug Could Reduce Cardiovascular Deaths

New Drug Could Reduce Cardiovascular Deaths

Newsy (Aug. 30, 2014) — The new drug from Novartis could reduce cardiovascular deaths by 20 percent compared to other similar drugs. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins